LIPO · Lipella Pharmaceuticals Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”View the 10-Q filed Nov 14, 2025
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $389.78K | $536.36K | $449.62K | $184.16K | $259.35K | |
| $3.57M | $3.61M | $3.04M | $2.55M | $1.46M | |
| $2.23M | $2M | $2.16M | $226.19K | $718.38K | |
| $2886 | $2886 | $1685 | — | — | |
| -$5.41M | -$5.08M | -$4.75M | -$2.59M | -$1.92M | |
| — | -947.23% | -1055.55% | -1406.26% | -738.71% | |
| -$5.41M | -$5.08M | -$4.74M | — | — | |
| — | — | $10.85K | $9612 | $6834 | |
| $80.2K | $64.28K | $137.84K | $1678 | $104 | |
| $80.2K | $64.28K | $126.99K | -$7979 | $50.36K | |
| -$5.33M | -$5.02M | -$4.62M | -$2.6M | -$1.87M | |
| -$5.33M | -$5.02M | -$4.62M | -$2.6M | -$1.87M | |
| — | -935.25% | -1027.31% | -1410.59% | -719.3% | |
| USD/shares | -$2.43 | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| USD/shares | -$2.43 | -$4.79 | -$6.16 | -$5.12 | -$4.40 |
| shares | — | 1.05M | 750.38K | 507.58K | 426.01K |
| shares | — | 1.05M | 750.38K | 507.58K | 426.01K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2025-09-30 | USD 44,267 | 10-Q filed 2025-11-14 |
| Noncurrent operating lease liabilities | 2025-09-30 | USD 219,816 | 10-Q filed 2025-11-14 |
| Notes payable, including current maturities | 2025-09-30 | USD 0 | 10-Q filed 2025-11-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Grant Revenues | $536,357 | $449,617 | $184,156 | $259,347 |